Merck Provides International Partnership With Experimental Drug to Develop Microbicide
March 13, 2008
Merck has agreed to provide the International Partnership for Microbicides with its experimental antiretroviral drug L'644 to develop a microbicide that could protect women against HIV, the partnership announced on Tuesday, Reuters reports (Fox, Reuters, 3/11). Microbicides include a range of products -- such as gels, films and sponges -- that could help prevent the sexual transmission of HIV and other infections (Kaiser Daily HIV/AIDS Report, 2/26). L'644 is a member of a class of drugs known as gp41 fusion inhibitors, which block HIV from attaching to immune system cells.
IPM also has an agreement with Merck for a royalty-free license to develop the compound L'167/CMPD167, which belongs to the class of antiretrovirals called CCR5 inhibitors, Reuters reports (Reuters, 3/11). In addition, IPM has agreements with Pfizer for its antiretroviral maraviroc; with Gilead Sciences for its antiretroviral tenofovir; with Bristol-Myers Squibb; and with Johnson & Johnson subsidiary Tibotec Pharmaceuticals for its antiretroviral dapivirine (IPM release, 3/11).
Carraguard Ineffective for Preventing HIV Transmission, Study Finds; Researchers Say That Microbicide Research Should Continue
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.